CAAS
ACRS icon

Capital Asset Advisory Services’s Aclaris Therapeutics ACRS Stock Holding History

Capital Asset Advisory Services’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,844
Closed -$18K – 693
2020
Q4 		$18K Buy
+2,844
New +$12K ﹤0.01% 903

Other funds holding ACRS

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Capital Asset Advisory Services's ACRS Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Aclaris Therapeutics (ACRS) in Q1 2021, closing a stake of 2,844 shares — an estimated $18K sold.

Capital Asset Advisory Services first reported a position in ACRS in Q4 2020 and held it in 1 quarter. The position peaked at $18K in Q4 2020. 97 funds tracked by Wall St. Rank hold ACRS as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining Aclaris Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 2,844 Aclaris Therapeutics shares in Q1 2021, an estimated $18K.
  • Capital Asset Advisory Services first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's Aclaris Therapeutics position peaked at $18K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.